Journal: Journal of Inflammation Research

Article Title: Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases

doi: 10.2147/jir.s286110

Figure Lengend Snippet: Figure 5 Anti-inflammatory activity of LFA-9. Paw thickness (A) and percent inhibition (B) using inflammogen (carrageenan (CAR))-induced rat paw edema. (C) Effect of LFA-9 on PGE2, LTB4, PGI2, and TXB2 levels in exudates of carrageenan (CAR))-induced rat paw edema. (D) Effect of LFA-9 on expression of CD68 and TNF-α in CAR- injected paw tissue using immunoblot analysis. (E and F) Effect of LFA-9 on CD68-positive inflammatory cell infiltration and TNF-α expression in CAR-injected paw tissue sections using immunofluorescence technique. P-values ≤0.05 for data sets were considered significant. (NS) Not significant (P>0.05); *(P ≤ 0.05); **(P ≤ 0.01); *** (P ≤ 0.001); **** (P ≤ 0.0001). (G) Schematic representation of mechanism of action of LFA-9 for its anti-inflammatory activity with safety.

Article Snippet: After incubation with primary antibody [Alexa Fluor 700-conjugated CD68 (1:50 dilution) (Novus Biologicals (NB600985)) and TNF-α (1:100 dilution) (Santa Cruz)] overnight at 4°C, slides were labeled with Alexa Fluor 488 dye-conjugated secondary antibody (for TNF-α) and mounted with ProLong Gold (Thermo Fisher Scientific).

Techniques: Activity Assay, Inhibition, Expressing, Injection, Western Blot, Immunofluorescence

Journal: Communications Biology

Article Title: MicroRNA-221-3p inhibits the inflammatory response of keratinocytes by regulating the DYRK1A/STAT3 signaling pathway to promote wound healing in diabetes

doi: 10.1038/s42003-024-05986-0

Figure Lengend Snippet: Representative immunohistochemistry images ( a , b ) and summary data ( c , b ) showing myeloperoxidase (MPO) ( a , c ) and CD68 ( b , d ) expression levels on days 1, 3, 7, and 11 after wound formation in diabetic mice injected with miRNA mimic negative control (DM-Ctrl) or miR-221-3p agomir (DM-miR-221-3p). Density of positive cells was calculated using the following formula: number of positive cells/area size ( n = 4–6). Scale bars, 50 μm. Summary data showing relative mRNA expression levels of IL-1β, IL-6, IL-8 , and TNF-α at the edge of the skin wound on days 1 ( e ), 7 ( f ) and 11 ( g ) ( n = 6–10). h Summary data showing relative mRNA expression levels of CD86 and CD206 at the edge of the skin wound on days 11 ( n = 6–10). The mRNA levels were normalized to 18S ribosomal RNA. Data in c-h are presented as mean ± SEM. Solid circles represent DM-Ctrl group and squares, DM-miR-221-3p group. * P < 0.05, ** P < 0.01 for DM-miR-221-3p vs. DM-Ctrl.

Article Snippet: Sections were then incubated overnight at 4 °C with primary antibody CD68 (NB600-985, Novus Biologicals, USA), MPO (AF3667, Abcam, UK) or DYRK1A (DF3270, Affinity Biosciences, China) followed by incubation with a secondary antibody conjugated with streptavidin-horseradish peroxidase.

Techniques: Immunohistochemistry, Expressing, Injection, Negative Control

Journal: Communications Biology

Article Title: MicroRNA-221-3p inhibits the inflammatory response of keratinocytes by regulating the DYRK1A/STAT3 signaling pathway to promote wound healing in diabetes

doi: 10.1038/s42003-024-05986-0

Figure Lengend Snippet: Representative immunohistochemistry images and summary data showing myeloperoxidase (MPO) ( a ), CD68 ( b ) and DYRK1A ( c ) expression levels in skin wound tissues of wild type (WT) and Mir221 knockout (KO) mice. Data are presented as mean ± SEM ( n = 5–8). Scale bars, 50 μm in ( a , b ), 5 μm in ( c ). d Representative images and summary data showing expression levels of phosphorylated (p)-STAT3 (Tyr705), p-STAT3 (Ser727), total STAT3, and DYRK1A in skin wound tissues of WT and Mir221 KO mice. Vertically stacked strips of bands in a figure are not derived from the same membrane in any case. Data are presented as mean ± SEM ( n = 5), * P < 0.05.

Article Snippet: Sections were then incubated overnight at 4 °C with primary antibody CD68 (NB600-985, Novus Biologicals, USA), MPO (AF3667, Abcam, UK) or DYRK1A (DF3270, Affinity Biosciences, China) followed by incubation with a secondary antibody conjugated with streptavidin-horseradish peroxidase.

Techniques: Immunohistochemistry, Expressing, Knock-Out, Derivative Assay, Membrane